PURMX Therapeutics Initiates Phase I Clinical Trial of MIRX002, a Novel MicroRNA-Based Anticancer Drug, for Head and Neck Cancer

tomokokikuchi4
Mar 31
1 min read

PURMX Therapeutics, Inc. (hereinafter referred to as “PURMX”) (Head Office: 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima Prefecture; President: Hidetoshi Tahara), has announced that MIRX002, which is currently under development, has been administered to the first subject in a Phase I clinical trial for head and neck cancer, which has been underway for some time. The first subject has been administered and the study has started.

Recent Posts

See All

Raised funds through a third-party allocation of new shares from Keio Innovation Initiative, Inc.

PURMX Therapeutics, Inc. (PURMX Therapeutics; Headquarters: Hiroshima, Japan; President: Hidetoshi Tahara; hereafter “the Company”) is...

PURMX Therapeutics Raised Funds through a Third-party Allotment of New Shares from Yokohama Capital

We are pleased to announce that PURMX Therapeutics, Inc. (headquartered in Hiroshima City, Japan; Hidetoshi Tahara, President & CEO;...

PURMX Therapeutics Receives the "University Venture Award Special Prize" at the University Venture A

Opmerkingen